As demand for popular weight-loss drugs like Wegovy and Zepbound increases, their high cost and limited availability are driving many individuals to seek alternative, less regulated sources, according to a new survey conducted by Ohio State University researchers.
These injectable medications, known for their effectiveness in treating obesity, are becoming increasingly difficult to access due to supply shortages and prohibitive pricing. As a result, some people are bypassing their healthcare providers and turning to questionable online pharmacies and telehealth services.
The survey found that 1 in 4 people would consider using these weight-loss drugs without first consulting a doctor. Among the reasons for avoiding medical advice were the lower cost (18%), lack of insurance coverage (15%), inability to get a prescription (9%), and limited availability through traditional pharmacies (6%).
However, experts warn that obtaining medications from unlicensed sources or unreliable telehealth providers can be dangerous. Dr. Shengyi Mao, an internal medicine specialist at Ohio State, stressed the importance of consulting with a healthcare professional before starting any weight-loss drug.
“It’s crucial for individuals looking to lose weight to have an informed discussion with their doctor about their options,” Mao said. “Weight-loss medications are not a one-size-fits-all solution, and each drug can come with its own risks and side effects. A physician is best equipped to review a patient’s medical history and determine the safest and most effective treatment.”
The U.S. Food and Drug Administration (FDA) has already issued warnings in 2024 regarding compounded semaglutide, a modified version of the active ingredient in Wegovy and Ozempic, which has been linked to dosing errors resulting in severe side effects like nausea, vomiting, hypoglycemia, and hospitalizations. Compounded drugs are specially mixed or altered to fit the needs of individual patients, but this process can lead to improper dosing, complicating treatment further.
Additionally, some compounding pharmacies are using semaglutide salt, a different form of the active ingredient, which raises concerns about its efficacy and safety. The FDA is also investigating reports of counterfeit Ozempic being sold within the United States.
Dr. Mao highlighted that obesity is a complex chronic condition that should not be treated with a one-size-fits-all approach. “A comprehensive weight management program is typically the best route because losing weight and keeping it off requires significant lifestyle changes and a lifelong commitment,” she said.
While these weight-loss drugs may offer effective results for some, Mao emphasized that they can also carry serious side effects. Moreover, the weight lost while on the drug may return after discontinuation, further underscoring the importance of an integrated approach to weight management.
The findings of the survey, which was conducted between August 16 and 18 through web and telephone polling, involved 1,006 respondents. The results highlight a growing concern: as patients explore non-traditional methods to access these drugs, they are often putting themselves at risk without fully understanding the consequences.
As the popularity of these medications continues to rise, healthcare professionals are urging patients to rely on trusted sources and medical supervision to ensure both their physical and mental well-being during their weight-loss journey.
